In a revealing turn of events, CVS Health has been placed under scrutiny following a report by the House Judiciary Committee. The House Judiciary Committee GOP report, aptly titled "When CVS Writes the Rules: How CVS Protects Itself From Innovation and Competition," details the company's alleged tactics to sideline independent pharmacies and emerging rivals in the burgeoning digital pharmacy space.
The committee found that CVS Health used insights from nonpublic documents on the hub pharmacy model to change its network rules, effectively blocking independent pharmacies from collaborating with these new digital hubs. The company also used audits and cease-and-desist letters to further limit independent pharmacies’ options. CVS leveraged its position within the PBM (pharmacy benefit manager) network to restrict competition, though it has since allowed limited collaboration between independent pharmacies and at least one digital pharmacy hub.
According to the House Judiciary Committee GOP, CVS Health’s actions regarding digital pharmacy innovations and hub models may fall under current antitrust laws, though questions remain about whether the existing framework is sufficient. In internal communications made public, CVS Health’s CEO called it “another example of a large PBM not allowing the small guys to compete.”
This case highlights broader challenges in the healthcare and pharmaceutical sectors, where lawmakers are considering whether new antitrust legislation is needed. CVS Health’s partial allowance for independent pharmacies to work with one hub illustrates potentially restrictive practices. While it is unclear whether these actions will lead to legal consequences, they have prompted renewed scrutiny of whether current antitrust laws are sufficient to address such behavior.
